Processa Pharmaceuticals Inc Stock Price, News & Analysis

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced its participation in two upcoming investor conferences. They will attend the Craig-Hallum Virtual Institutional Investor Conference on June 2, focusing on one-on-one meetings. Additionally, they will present at the Jefferies Virtual Healthcare Conference on June 4, from 2:00 to 2:25 PM EST, where one-on-one meetings will also be available. The company is committed to developing products to enhance survival and quality of life for patients with unmet medical needs.

Processa Pharmaceuticals (NASDAQ: PCSA) has dosed its first patient in a Phase 2B trial for PCS499, targeting ulcerations in patients with Necrobiosis Lipoidica (NL), a rare skin disease affecting collagen. The trial aims to assess the efficacy of PCS499 compared to a placebo. Approximately 30% of NL patients experience open ulcers that impair quality of life. Sian Bigora, Chief Development Officer, expressed optimism about the trial's potential impact on treatment options for this underserved condition.

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced its participation in two investor conferences aimed at addressing unmet medical needs. The events include the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021 (on-demand presentations) and The Benchmark Company Healthcare House Call Virtual Conference on May 26, 2021 (one-on-one meetings). Processa focuses on developing treatments for conditions such as metastatic colorectal cancer, breast cancer, and GI motility disorders. The company aims to enhance patient survival and quality of life through existing clinical evidence.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) reported financial results for the first quarter ended March 31, 2021, showcasing significant advancements in its clinical drug pipeline. The company has commenced trials for its product candidates PCS6422 and PCS499, targeting markets exceeding $1 billion each. As of March 31, 2021, cash and equivalents reached $23 million, compared to $15.4 million at year-end 2020. The company reported a net loss of $2.1 million for the quarter. Upcoming milestones include the submission of an IND application for PCS12852 and interim trial results for PCS6422 by late 2021.

Processa Pharmaceuticals (NASDAQ: PCSA) will host a conference call on May 13, 2021, at 5:30 PM EST to discuss its Q1 2021 results and provide updates on its clinical pipeline. The call can be accessed via a toll-free number or an international line. The company focuses on developing products to improve survival and quality of life for patients with unmet medical needs, with active pipeline programs for conditions like metastatic colorectal cancer, breast cancer, and GI motility disorders.

Processa Pharmaceuticals reported significant progress in 2020, including the in-licensing of three programs with potential markets exceeding $1 billion each. The company anticipates dosing the first patients for PCS6422 and PCS499 in Q2 2021. Financial results show a net loss of $14.4 million, compared to $3.4 million in 2019. Processa's cash and equivalents stood at $15.4 million at year-end 2020, bolstered by recent fundraising totaling $27.3 million. Key upcoming milestones include FDA submissions and interim results for the ongoing clinical trials.

Processa Pharmaceuticals (NASDAQ: PCSA) will host a conference call on March 25, 2021, at 5:30 p.m. ET to discuss its fourth quarter 2020 results and clinical pipeline updates. Investors can join the call via a toll-free number or through a live webcast. Processa focuses on developing products for patients with unmet medical needs, with programs targeting cancers and gastrointestinal disorders. The company highlights its experienced development team, which has been involved with over 30 FDA drug approvals.

Processa Pharmaceuticals has selected 5 U.S. clinical sites for its Phase 2B trial of PCS499, aimed at treating ulcerative necrobiosis lipoidica. The trial, led by Dr. Misha Rosenbach, will evaluate the efficacy and safety of PCS499, with patient recruitment expected to start within 30-60 days. The condition affects the skin and can cause painful ulcerations, with no effective treatments currently available. Preliminary evaluations suggest PCS499 may close ulcers within months, which could significantly improve patient outcomes.

Processa Pharmaceuticals (Nasdaq: PCSA) has successfully closed a private placement raising $10.2 million by selling 1,321,132 shares at $7.75 each. The net proceeds amount to $9.9 million, which will finance clinical developments of PCS6422 and PCS11T through 2023. CEO David Young expressed gratitude to investors, highlighting the potential of these drugs in treating cancers such as colorectal and breast cancer. The offering was conducted under SEC exemptions, and a registration statement will be filed for resale of shares.